NHS Blood and Transplant Bristol Centre, Bristol, UK.
Br J Haematol. 2009 Oct;147(1):71-6. doi: 10.1111/j.1365-2141.2009.07832.x. Epub 2009 Aug 13.
Haematopoietic stem cell transplantation (HSCT) is widely used to treat patients with a range of haematological and non-haematological disorders. Both bone marrow and peripheral blood stem cell collection are associated with morbidity and, very rarely, mortality. We investigated the information that exists to adequately inform donors about the relative merits of each procedure. We carried out a systematic review analysing data from six prospective randomised controlled trials of related donors and discuss here the merits and drawbacks of this approach. Registry data mostly describes patient outcome but stem cell donor registries collect and report information on unrelated donors which could easily be extended to related donors. Further well-designed, randomised studies are required.
造血干细胞移植(HSCT)被广泛用于治疗各种血液系统和非血液系统疾病的患者。骨髓和外周血干细胞采集都与发病率有关,极少数情况下还会导致死亡。我们调查了现有的信息,以充分告知供者每种程序的相对优点。我们进行了一项系统评价,分析了来自六个相关供者的前瞻性随机对照试验的数据,并在此讨论了这种方法的优缺点。注册数据主要描述了患者的结局,但干细胞供者登记处收集和报告了无关供者的信息,这些信息很容易扩展到相关供者。需要进一步进行设计良好的随机研究。